Skip to main content
  1. Home
  2. Emerging Tech
  3. News

Digital Trends may earn a commission when you buy through links on our site. Why trust us?

Startup creates $135 coronavirus test you can take at home

Add as a preferred source on Google
 

In response to a mass shortage of available tests, a U.S. medical-testing startup will soon offer a direct-to-consumer test for the coronavirus, officially known as COVID-19. 

Recommended Videos

The company, called Everlywell, will initially have 30,000 tests available to purchase online starting Monday, March 23. Tests will be priced at $135, which includes overnight sample delivery, according to Everlywell’s press release. 

People will have to go through an initial screening before they can purchase a test, which would include questions based on coronavirus guidelines from the Centers for Disease Control and Prevention (CDC). Results will be available online within 48 hours of the company receiving the test, and those who test positive can virtually connect with a physician for free. 

Everywell

Everlywell said that it worked with top scientists and laboratories to develop the test. The U.S. is facing disorganized coronavirus testing, as well as an overall shortage of tests. 

The extreme shortage of tests for COVID-19 puts millions of Americans at risk. Everlywell is committed to helping stop the spread of COVID-19 in the U.S. by making this test widely available. As the national leader in at-home lab testing, we want to use our resources and expertise to help as many people as we can. We are committed to this fight, and we’re here to help, ”said Julia Cheek, founder and CEO of Everlywell, in the company’s press release. 

Cheek added that Everywell would not profit from the coronavirus tests and that it reached out to government and public health officials to find out how it can offer the test for free. 

The company is known for making at-home tests for a variety of diseases and ailments, including Lyme Disease, food sensitivity, STDs, fertility, and more. 

An Everywell spokesperson told Digital Trends that the coronavirus test was reviewed by the Food and Drug Administration (FDA).

“All of Everlywell’s laboratory partners conducting COVID-19 testing have had their validation data and reports reviewed by the FDA under the Emergency Use Authorization (EUA) framework,” the spokesperson said.

The FDA and the CDC did not immediately respond to our request for comment on Everlywell’s coronavirus test. We will update this story when we hear back.

Testing in the U.S. is nowhere near where it needs to be, and Microsoft co-founder Bill Gates said that getting the U.S. organized on testing will allow us to overcome the rapid spread of the coronavirus. Estimates suggest fewer than 10,000 Americans have been tested, significantly fewer than the 20,000 per day tested in South Korea.

As of this writing, there have been more than 230,050 confirmed cases of the coronavirus worldwide, and 9,358 confirmed deaths, according to an online dashboard that tracks cases. 

Allison Matyus
Former Digital Trends Contributor
Allison Matyus is a general news reporter at Digital Trends. She covers any and all tech news, including issues around social…
Students who use AI every day may be falling behind, while moderate users pull ahead
New global testing data suggests more AI in the classroom isn't automatically better.
Logo, Text

I assumed more AI access might help students learn faster. However, a new OECD study dispels that misconception for me and everyone else who gave their children a paid version of AI chatbots, thinking it would help them through their educational journey. 

According to PISA 2025 data from 760,000 students in 91 countries, students who use AI daily score meaningfully worse on standardized tests than their peers. The full picture is more complicated than a simple ban would fix.

Read more
XPENG just put its humanoid robot on the production line, and it walked itself out
IRON clocks in for its first shift
XPENG Iron

XPENG’s humanoid robot has officially joined the workforce, and it even got an employee badge. The Chinese automaker announced on September 8 that its next-generation IRON had completed assembly and autonomously walked off its newly commissioned humanoid robot production line in Guangzhou.

CEO He Xiaopeng then pinned a staff badge onto the robot, symbolically welcoming it to the XPENG team. It is a charming little ceremony for a machine that the company hopes will eventually become a regular part of everyday life. XPENG is moving IRON beyond R&D prototypes toward production-line manufacturing, applying the quality-control systems and manufacturing experience it has developed through its electric vehicle business.

Read more
An AI-designed drug might help slow aging, but we’re not there yet
The results hint at a possible anti-aging effect, but there’s still a long way to go before we know what it means.
medical test tubes

Rentosertib, a drug Insilico Medicine designed almost entirely using AI, was created to treat idiopathic pulmonary fibrosis, a disease that scars and stiffens the lungs over time. But fighting lung disease was only half the plan from the start.

According to a new study published in Nature Biotechnology, the drug's target was chosen specifically because it overlaps heavily with the biology of aging, and the whole trial was designed to test whether treating the lungs could also mean turning back the body's biological clock.

Read more